Home > Oncology > ESMO 2021 > Gastrointestinal Cancer > Immune chemo-sensitisation looks promising in microsatellite-stable mCRC

Immune chemo-sensitisation looks promising in microsatellite-stable mCRC

Presented By
Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori di Milano, Italy & Dr Chiara Cremolini, Azienda Ospedaliero-Universitaria Pisana, Italy
Conference
ESMO 2021
Trial
Phase 2, MAYA & AtezoTRIBE
Both MAYA and AtezoTRIBE, phase 2 trials reporting on new immunotherapy-containing approaches to treatment for patients with proficient mismatch repair (pMMR)/microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), met their primary endpoint of progression-free survival (PFS). Almost all MSS colorectal cancers are refractory to immunotherapy and combination strategies to turn these so-called ‘cold’ tumours into ‘hot’ – i.e. immune-responsive – tumours have failed so far. Inactivation of the MGMT gene by hypermethylation enhances sensitivity for alkylation agents such as temozolomide (TMZ) [1]. Secondary resistance to TMZ may induce a hypermutated status coupled with acquired mutations in MMR genes in diverse tumour types, including CRC [2]. Therefore, the induction of hypermutation by a TMZ priming phase provides the rationale for immune-sensitisation of MSS mCRC. The single-arm MAYA trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on